BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

804 related articles for article (PubMed ID: 22500372)

  • 21. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease.
    Keino H; Okada AA; Watanabe T; Taki W
    Eye (Lond); 2014 Sep; 28(9):1100-6. PubMed ID: 24946845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
    Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
    Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
    Tognon S; Graziani G; Marcolongo R
    Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis.
    Schaap-Fogler M; Amer R; Friling R; Priel E; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):633-40. PubMed ID: 24366669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical observation of 85 patients with Behçet's uveitis treated with immunosuppressive agents combined with steroids].
    Zhao M; Wang H; Jiao X; Wei WB
    Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):202-6. PubMed ID: 23866699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of regulatory T cells by infliximab in Behcet's disease.
    Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-TNF-alpha therapy for sight threatening uveitis.
    Lindstedt EW; Baarsma GS; Kuijpers RW; van Hagen PM
    Br J Ophthalmol; 2005 May; 89(5):533-6. PubMed ID: 15834077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.
    Markomichelakis N; Delicha E; Masselos S; Fragiadaki K; Kaklamanis P; Sfikakis PP
    Rheumatology (Oxford); 2011 Mar; 50(3):593-7. PubMed ID: 21097877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Uveitic glaucoma in Behçet's disease: When everything gets complicated].
    Belkhadir K; Boutimzine N; Tachfouti S; Laghmari M; Amazouzi A; Cherkaoui O
    J Fr Ophtalmol; 2020 Sep; 43(7):635-641. PubMed ID: 32622636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
    Tabbara KF; Al-Hemidan AI
    Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frosted branch angiitis and cerebral venous sinus thrombosis as an initial onset of neuro-Behçet's disease: a case report and review of the literature.
    Ferreira BFA; Rodriguez EEC; Prado LLD; Gonçalves CR; Hirata CE; Yamamoto JH
    J Med Case Rep; 2017 Apr; 11(1):104. PubMed ID: 28410605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conventional immunosuppressive therapy in severe Behcet's Uveitis: the switch rate to the biological agents.
    Celiker H; Kazokoglu H; Direskeneli H
    BMC Ophthalmol; 2018 Oct; 18(1):261. PubMed ID: 30290779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
    Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.
    Gül A; Tugal-Tutkun I; Dinarello CA; Reznikov L; Esen BA; Mirza A; Scannon P; Solinger A
    Ann Rheum Dis; 2012 Apr; 71(4):563-6. PubMed ID: 22084392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
    Interlandi E; Leccese P; Olivieri I; Latanza L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.
    Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Hanami K; Tanaka Y
    Mod Rheumatol; 2011 Apr; 21(2):184-91. PubMed ID: 21052764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
    Fabiani C; Vitale A; Emmi G; Vannozzi L; Lopalco G; Guerriero S; Orlando I; Franceschini R; Bacherini D; Cimino L; Soriano A; Frediani B; Galeazzi M; Iannone F; Tosi GM; Salvarani C; Cantarini L
    Clin Rheumatol; 2017 Jan; 36(1):183-189. PubMed ID: 27853889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.